Ávila CMC, Soto AV, Fortoul T

Language: Spanish
References: 13
Page: 474-477
PDF size: 54.69 Kb.

ABSTRACT

The incidence of chronic rheumatic heart disease has declined remarkably worldwide. Epidemiology of valvular heart disease has been changing recently due to the improvement of socioeconomic conditions and general changes on public health in different countries. Chronic rheumatic valvulopathy was present only in 30% of the cases prospectively studied between 2001 and 2003 at the Instituto Nacional de Cardiologia “Ignacio Chavez” in Mexico. Objective: To review several non-rheumatic valvulopaties with an increasing incidence in different centers worldwide. Heart valve lesions in patients with antiphospholipid syndrome have been reported to have a high prevalence in patients with systemic lupus erithematosus as well as the primary form. A multicentre prospective echocardiografic study showed a significant prevalence of valvulopathy. The pathogenesis of the lesion includes direct endothelial damage. Valvular heart disease induced by anorectic drugs has also been described. Pathogenesis seems to be related with the serotonin levels in circulation, as described in the carcinoid syndrome affecting the heart. Cardiac involvement in HIV-infected patients can be appreciated early. Three different types of valvulopathy have been described. There is one type similar to the one decribed in antiphospholipid antibody syndrome.

REFERENCES

1. Schoen FJ, Edwards W: Valvular heart disease: General principles and stenosis. In: Silver MD Editor. Cardiovascular Pathology, 3era. Ed. New York. Churchill Livingstone, 2001:p 402-440.

2. Álvarez-Blanco A, Egurbide-Arberas V, Aguirre-Errasti C: Several valvular Heart disease in a patient with primary antiphospholipid syndrome. Lupus 1994; 3: 433-434.

3. Asherson R, Cervera R: Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation 1991; 84: 920-923.

4. Cervera R, Khamashta MA, Font J, Reyes PA, Vianna JL, López-Soto A, Amigo MC, Asherson RA, Azqueta M, Paré C, Vargas J, Romero A, Ingelmo M, Hughes G: High prevalence of significant heart valve lesions in patients with the “primary” antiphospholipid syndrome. Lupus 1991; 1: 43-47.

5. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD: Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 1989; 86: 407-412.

6. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002; 346: 756-763.

7. Rosenbaum M, Leibel RL, Hirsch J: Obesity (review). N Engl J Med 1997; 337: 397.

8. Connolly HM, Crary JL, McGoon MD: Valvular heart disease associated with fenfluoramine-phentermine. N Engl Med 1997; 337: 581-84.

9. Khan MA, Herzog CS, St Peter JV: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339: 713-16.

10. Robiolio PA, Rigolin VH, Wilson JS: Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac auscultation and echocardiography. Circulation 1995; 92: 790-93.

11. Rothman RB, Baumann MH, Savage JE, Rauser L, MacBride A, Hufeisen SJ, Roth PL: Evidence for possible involvement of 5-HT2b receptors in the cardiac valvulopathy associated with fenfluoramine and other serotonergic medications. Circulation 2000; 102: 2836-2841.

12. Cammarosano C, Lewis W: Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol 1985; 5: 703-706.

13. Currie PF, Sutherland GR Jacob AJ: A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J 1995; 16 (Suppl B): 15-18.